perimenopause and glp 1 GLP-1 Agonists in Perimenopause: Unique Risks Potential Opportunities GLP-1 and Perimenopause: Clinical Evidence
Description
The lawsuits against Novo Nordisk and Eli Lilly primarily revolve around the claim that these companies failed to adequately warn patients of the potential risks associated with Ozempic and other similar drugs
Class III: high solubility, low permeability
We forecast that that demand is going to grow further
Staffing is also key: linking experienced personnel from the sending site to the receiving site prevents knowledge gaps
